Apolipoprotein O and fragments thereof for inducing apoptosis in a cancerous cell
View Patent ↗The invention relates to a compound for use for inducing apoptosis in a cancerous cell, wherein said compound is selected from the group consisting of ApoO, a variant or a fragment thereof, their mixtures, and a vector encoding for said ApoO, variant or fragment thereof. The invention further relates to a compound for use for treating a pathophysiological situation, wherein said compound is an inhibitor of the ApoO activity or of the ApoO gene expression.
1. A method for inducing apoptosis in a cancerous cell comprising a step of administering, in an effective amount to induce apoptosis of said cancerous cell, a compound selected from the group consisting of Apolipoprotein O (ApoO), a polypeptide comprising an ApoO fragment which induces apoptosis comprising at least one of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, and mixtures thereof.
2. The method according to claim 1 wherein said method is for treating cancer.
3. A method according to claim 1 , wherein said cancerous cell is selected from the group consisting of heart cell, liver cell, bladder cell, brain cell, breast cell, colon cell, rectum cell, endometrium cell, kidney cell, blood cell, epidermis cell, pancreas cell, prostate cell and thyroid cell.
4. A method according to claim 1 , wherein said cancerous cell is a brain cancer cell, said brain cancer being selected from brain cancers includes chordomas, craniopharyngiomas, gangliocytomas, gangliomas, anaplastic gangliogliomas, glomus jugulare, meningiomas, pineocytomas, pituitary adenomas, schwannomas, glioma, hemangioblastomas and rhabdoid tumors.
5. A method according to claim 1 , wherein said cancerous cell is selected from the group consisting of astrocytes, ependymal cells and oligodendroglial cells.
6. A method according to claim 1 , wherein said cancer is glioblastoma.
7. A method according to claim 1 , wherein said compound is a human ApoO as depicted in SEQ ID NO: 1.
8. A method according to claim 1 , wherein said compound is said polypeptide comprising an ApoO fragment, said fragment having a length between 30 to 190 amino acids.
9. The method according to claim 8 , wherein said fragment has a length between 50 and 130 amino acids.
10. The method according to claim 9 , wherein said fragment has a length between 70 and 120 amino acids.
11. A method according to claim 1 , wherein said compound is said polypeptide comprising an ApoO fragment, said fragment having a length between 8 to 190 amino acids.
12. The method according to claim 11 , wherein said fragment has a length between 8 and 100 amino acids.
13. The method according to claim 12 , wherein said fragment has a length between 8 and 50 amino acids.
14. A method according to claim 1 , wherein said compound is the fragment of ApoO depicted in SEQ ID NO: 12.
15. A method according to claim 1 , wherein said compound is ApoO or a fragment thereof comprising at least one of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12 and further comprising at least the first 40 contiguous amino acids of ApoO.
16. The method according to claim 1 , wherein said compound consists of SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.
17. A method according to claim 1 , wherein said compound interacts with mitochondrial permeability transition pore (MPTP), driving MPTP to adopt an open state thereby inducing mitochondrial uncoupling.
18. A method according to claim 1 , wherein said compound interacts with Cyclophillin D (CyPD) and/or adenine nucleotide translocase (ANT).
19. A method according to claim 1 , wherein said compound increases mitochondrial respiration, increases fatty acid metabolism and induces lipid accumulation within said cancerous cells.